|   From the Trenches

Targeted Protein Degradation: The First Proof-of-Mechanism in a Randomized, Placebo-Controlled Study

The inherent ability to combine the power of genetic-like knockdown with the flexibility of small molecules; the power to drug classes of targets that have been elusive to other therapeutic modalities; the use of affinity rather than occupancy-based catalysis – the promise of these advantages has made targeted protein degradation one of the most exciting new therapeutic modalities of the past 30 years.

By Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   In the News

Hitting landmark milestone, Intellia shows CRISPR can edit genes directly in patients

In a landmark study, researchers successfully used CRISPR to directly edit DNA in humans, a milestone that could pave the way for treatments for scores of serious genetic and non-genetic diseases.

Read more.


  |   From the Trenches

The First Born

I was in the passenger seat, trying desperately not to reach for the grab handle, saying reassuring things but thinking ‘those mailboxes are really close’.

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC

Read more.


  |   From the Trenches

Rethinking Your Professional Health: Having An Executive Coach Is A Gift, Not A Gap

Spring in New England is in full bloom. All around birds are chirping, flowers are blooming, and there is sweetness (and pollen) everywhere. Life is anew. Really anew. I don’t know about you, but this spring feels particularly poignant. The pandemic isolation was long, personal, and collectively traumatic. Having the seasonal change of nature’s new life coincide with vaccinations climbing and COVID cases decreasing, has me almost sprinting back to the office.

By Andrea DiMella, VP and Head of Talent at Atlas Venture, as part of the From The Trenches feature of LifeSciVC.

Read more.

 


  |   LifeSciVC

Biotech’s Relevancy Challenge In An Expanding Universe

By Bruce Booth, DPhil, Partner

The universe of public biotech companies has been growing for a decade, and increasingly so in the past few years as the IPO market has flourished. Hundreds of young aspiring biotechs have tapped into the public equity markets, swelling the ranks of small- and mid-cap players.

Read more.